Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)
Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience. Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug delivery systems, technologies and products utilizing advanced drug delivery systems The report describes the industry, its relationship to various healthcare channels, and the trends for the future.
The advanced drug delivery market is two-fold. First of all it identifies drug delivery technology Secondly, it identifies products in the pharmaceutical arena that utilize those drug delivery technologies. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales. This report will provide market data that includes the pharmaceutical revenues of those products that utilize advanced drug delivery.In this report, the advanced drug delivery market is divided into three main segments and market estimates are provided for indications within each category:
The following types of polymer delivery drugs are segmented within this report.
A wide range of trends and issues that will impact the advance drug delivery market are discussed in the report including the current state of biotechnolgy expansion, molecular imprinted polymers, hot-melt extrusion, metallofullerenes, nanotechnology advancements and other emerging Drug Delivery technologies not yet on the market.
The following companies are profiled in the report:
The research conducted by Kalorama Information included comprehensive research of primary and secondary sources such as interviews with company executives, company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and data-based searches, as well as via interviews with key personnel. Person-to-person and telephone interviews were the primary method of gathering information. E-mail correspondence was also used in the interview process. Interviews with 24 key industry officials, trade association spokespersons, consultants, healthcare providers, and government personnel were compiled to form the primary basis of information - particularly revenue and market share data- presented in this report.
All market data pertains to the worldwide market at the manufacturers’ level and was measured in U.S. dollars. The base year for data was 2010. Historical data are provided for 2006 through 2009, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGR) are provided for the 2006-2010, 2010-2014 and 2006-2014.
The advanced drug delivery market is two-fold. First of all it identifies drug delivery technology Secondly, it identifies products in the pharmaceutical arena that utilize those drug delivery technologies. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales. This report will provide market data that includes the pharmaceutical revenues of those products that utilize advanced drug delivery.In this report, the advanced drug delivery market is divided into three main segments and market estimates are provided for indications within each category:
- Liposome Drug Delivery (by Indication - Fungal Infections Cancer, Others)
- Polymer Drug Delivery (by Indication - Cancer, Neutropenia, Hepatitis, Contraception, Schizophrenia, Acromegaly and Others)
- Monoclonal Antibodies Drug Delivery (by Indication - Arthritis, Cancer, Multiple Sclerosis, Macular Degeneration, Respiratory Syncytial Virus, Others)
The following types of polymer delivery drugs are segmented within this report.
- PEGylated Delivery
- Emulsuion Delivery
- Injectable Delivery
- Nanoparticle Delivery
- Others
A wide range of trends and issues that will impact the advance drug delivery market are discussed in the report including the current state of biotechnolgy expansion, molecular imprinted polymers, hot-melt extrusion, metallofullerenes, nanotechnology advancements and other emerging Drug Delivery technologies not yet on the market.
The following companies are profiled in the report:
- Alkermes, Inc.
- ALZA Corporation
- AP Pharma
- Centocor Ortho Biotech, Inc.
- Eisai , Inc
- Elan Corporation, Plc
- EnColl Corporation, Inc.
- Enzon Pharmaceuticals, Inc
- Gilead Sciences, Inc.
- Nektar Therapeutics
- PDL BioPharma
- pSivida Corp
- SurModics, Inc
- Tolmar, Inc
The research conducted by Kalorama Information included comprehensive research of primary and secondary sources such as interviews with company executives, company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and data-based searches, as well as via interviews with key personnel. Person-to-person and telephone interviews were the primary method of gathering information. E-mail correspondence was also used in the interview process. Interviews with 24 key industry officials, trade association spokespersons, consultants, healthcare providers, and government personnel were compiled to form the primary basis of information - particularly revenue and market share data- presented in this report.
All market data pertains to the worldwide market at the manufacturers’ level and was measured in U.S. dollars. The base year for data was 2010. Historical data are provided for 2006 through 2009, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGR) are provided for the 2006-2010, 2010-2014 and 2006-2014.
CHAPTER ONE: EXECUTIVE SUMMARY
Overview
Market Drivers
Market Size and Growth
Market Trends
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Introduction
Scope and Methodology
Reasons for Advanced Drug Delivery Systems
Phases of Drug Action
CHAPTER THREE: LIPOSOME DRUG DELIVERY
Overview
Liposome Targeting
Passive Targeting
Active Targeting
New Developments
Market Summary
Liposome Market by Indication
Liposome Market Competitive Analysis
CHAPTER FOUR: POLYMER DRUG DELIVERY
Overview
Polymeric Implants
Biodegradable Polymers
Nano- and Microparticulates
Polymer Micelles
PEGylation Technology
Hydrogel Polymers
Colloidal systems
PLA, PLG, and PLGA
Emulsions
Proteinaceous microparticles
New Developments
Market Summary
Market for Polymers by Product Type
Polymer Market by Indication
Polymer Market Competitive Analysis
CHAPTER FIVE: MONOCLONAL ANTIBODY DRUG DELIVERY
Overview
New Developments
Market Summary
Monoclonal Antibody Market by Indication
Monoclonal Antibody Market Competitive Analysis
CHAPTER SIX: TRENDS AND TECHNOLOGY DEVELOPMENTS
Expansion of Biotechnology
Incorporation of Technology
Molecular Imprinted Polymers
Antibiotic Biodegradable Implants
Hot-melt Extrusion Technology
Sorbent Technology
Gene Therapy Drug Delivery
Metallofullerenes
Antisense Delivery Systems
Nanotechnology advancements
Camouflaged Nanoparticles
Triggerable Drug Delivery
Prodrug Drug Delivery
Single Chain Antigen-Binding Protein Technology
Heat Shock Protein Technology
Other Emerging Drug Delivery Technologies
CHAPTER SEVEN: MARKET SIZE AND GROWTH
Total Market Summary
Geogrpahical Market Growth Summary Competitive Growth Analysis
CHAPTER EIGHT: COMPANY PROFILES
Alkermes, Inc.
ALZA Corporation
AP Pharma
Centocor Ortho Biotech, Inc.
Eisai , Inc
Elan Corporation, Plc
EnColl Corporation, Inc.
Enzon Pharmaceuticals, Inc
Gilead Sciences, Inc.
Nektar Therapeutics
PDL BioPharma
pSivida Corp
SurModics, Inc
Tolmar, Inc
APPENDIX: COMPANY DIRECTORY
Overview
Market Drivers
Market Size and Growth
Market Trends
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Introduction
Scope and Methodology
Reasons for Advanced Drug Delivery Systems
Phases of Drug Action
CHAPTER THREE: LIPOSOME DRUG DELIVERY
Overview
Liposome Targeting
Passive Targeting
Active Targeting
New Developments
Market Summary
Liposome Market by Indication
Liposome Market Competitive Analysis
CHAPTER FOUR: POLYMER DRUG DELIVERY
Overview
Polymeric Implants
Biodegradable Polymers
Nano- and Microparticulates
Polymer Micelles
PEGylation Technology
Hydrogel Polymers
Colloidal systems
PLA, PLG, and PLGA
Emulsions
Proteinaceous microparticles
New Developments
Market Summary
Market for Polymers by Product Type
Polymer Market by Indication
Polymer Market Competitive Analysis
CHAPTER FIVE: MONOCLONAL ANTIBODY DRUG DELIVERY
Overview
New Developments
Market Summary
Monoclonal Antibody Market by Indication
Monoclonal Antibody Market Competitive Analysis
CHAPTER SIX: TRENDS AND TECHNOLOGY DEVELOPMENTS
Expansion of Biotechnology
Incorporation of Technology
Molecular Imprinted Polymers
Antibiotic Biodegradable Implants
Hot-melt Extrusion Technology
Sorbent Technology
Gene Therapy Drug Delivery
Metallofullerenes
Antisense Delivery Systems
Nanotechnology advancements
Camouflaged Nanoparticles
Triggerable Drug Delivery
Prodrug Drug Delivery
Single Chain Antigen-Binding Protein Technology
Heat Shock Protein Technology
Other Emerging Drug Delivery Technologies
CHAPTER SEVEN: MARKET SIZE AND GROWTH
Total Market Summary
Geogrpahical Market Growth Summary Competitive Growth Analysis
CHAPTER EIGHT: COMPANY PROFILES
Alkermes, Inc.
ALZA Corporation
AP Pharma
Centocor Ortho Biotech, Inc.
Eisai , Inc
Elan Corporation, Plc
EnColl Corporation, Inc.
Enzon Pharmaceuticals, Inc
Gilead Sciences, Inc.
Nektar Therapeutics
PDL BioPharma
pSivida Corp
SurModics, Inc
Tolmar, Inc
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: The Global Market for Advanced Drug Delivery 2006-2014
Figure 1-1: The Global Market for Advanced Drug Delivery 2006-2014
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Table 2-1: Sequence of Drug Action
CHAPTER THREE: LIPOSOME DRUG DELIVERY
Table 3-1: Marketed Liposome Drugs, as of October 2010
Table 3-2: New Developments in Liposome Drugs
Table 3-3: The Global Market for Liposomes 2006-2014
Figure 3-1: The Global Market for Liposomes 2006-2014
Table 3-4: The Global Market for Liposomes by Indication, 2006-2010
Figure 3-2: The Global Market for Liposomes by Indication, 2006-2010
Figure 3-3: Market for Liposomes by Indication 2006
Figure 3-4: Market for Liposomes by Indication 2010
Table 3-5: Advanced Drug Delivery: Liposome Market—Competitors Revenues and Market Shares 2009
Figure 3-5: Advanced Drug Delivery: Liposome Market—Competitor Market Shares 2009
CHAPTER FOUR: POLYMER DRUG DELIVERY
Table 4-1: Marketed Biodegradable Polymer Drugs, as of October 2010
Table 4-2: Marketed Nano- and Micro-particle Drugs, as of October 2010
Table 4-3: Marketed PEGylated Drugs, as of October 2010
Table 4-4: Marketed Hydrogel Polymer Drugs, as of October 2010
Table 4-5: Marketed Emulsions, as of October 2010
Table 4-6: New Developments in Polymers
Table 4-7: The Global Market for Polymers 2006-2014
Figure 4-1: The Global Market for Polymers 2006-2014
Table 4-8: Market for Polymers by Product Type 2006-2014
Figure 4-2: Market for Polymers by Product Type 2006-2014
Figure 4-3: Market for Polymers by Product Type 2010
Table 4-9: The Global Market for Polymers by Indication, 2006-2010
Figure 4-4: The Global Market for Polymers by Indication, 2006-2010
Figure 4-5: Market for Polymers by Indication 2006
Figure 4-6: Market for Polymers by Indication 2010
Table 4-10: Advanced Drug Delivery: Polymer Market—Competitors Revenues and Market Shares 2009
Figure 4-7: Advanced Drug Delivery: Polymer Market—Competitor Market Shares 2009
CHAPTER FIVE: MONOCLONAL ANTIBODY DRUG DELIVERY
Table 5-1: Key Marketed Monoclonal Antibodies, as of October 2010
Table 5-2: New Developments in Monoclonal Antibodies
Table 5-3: The Global Market for Monoclonal Antibodies 2006-2014
Figure 5-1: The Global Market for Monoclonal Antibodies 2006-2014
Table 5-4: The Global Market for Monoclonal Antibodies by Indication, 2006-2010
Figure 5-2: The Global Market for Monoclonal Antibodies by Indication, 2006-2010
Figure 5-3: Market for Monoclonal Antibodies by Indication 2006
Figure 5-4: Market for Monoclonal Antibodies by Indication 2010
Table 5-5: Advanced Drug Delivery: Monoclonal Antibody Market—Competitors Revenues and Market Shares 2009
Figure 5-5: 108 Advanced Drug Delivery: Monoclonal Antibody Market—Competitor Market Shares 2009
CHAPTER SIX: TRENDS AND TECHNOLOGY DEVELOPMENTS
Table 6-1: Nanotechnology Drug Delivery 2010, Companies and Technology
CHAPTER SEVEN: MARKET SIZE AND GROWTH
Table 7-1: The Worldwide Market for Advanced Drug Delivery Systems Revenues by Type 2006-2014
Figure 7-1: 1 The Worldwide Market for Advanced Drug Delivery Systems Revenues by Type 2006-2014
Table 7-2: The Worldwide Market for Advanced Drug Delivery Systems Market Share by Type 2006-2014
Figure 7-2: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2006
Figure 7-3: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2010
Figure 7-4: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2014
Table 7-3: Worldwide Advanced Drug Delivery by Geographical Region, 2006-2010
Figure 7-5: Worldwide Advanced Drug Delivery by Geographical Region, Sales by Region, 2006-2010
Figure 7-6: Worldwide Advanced Drug Delivery by Geographical Region, Percent Sales by Region 2006
Figure 7-7: Worldwide Advanced Drug Delivery by Geographical Region, Percent Sales by Region 2010
Table 7-4: Worldwide Market for Advanced Drug Delivery System Revenues and Market Share by Supplier 2009
Figure 7-8: Worldwide Market for Advanced Drug Delivery Systems Market Share by Leading Supplier 2009
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: The Global Market for Advanced Drug Delivery 2006-2014
Figure 1-1: The Global Market for Advanced Drug Delivery 2006-2014
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Table 2-1: Sequence of Drug Action
CHAPTER THREE: LIPOSOME DRUG DELIVERY
Table 3-1: Marketed Liposome Drugs, as of October 2010
Table 3-2: New Developments in Liposome Drugs
Table 3-3: The Global Market for Liposomes 2006-2014
Figure 3-1: The Global Market for Liposomes 2006-2014
Table 3-4: The Global Market for Liposomes by Indication, 2006-2010
Figure 3-2: The Global Market for Liposomes by Indication, 2006-2010
Figure 3-3: Market for Liposomes by Indication 2006
Figure 3-4: Market for Liposomes by Indication 2010
Table 3-5: Advanced Drug Delivery: Liposome Market—Competitors Revenues and Market Shares 2009
Figure 3-5: Advanced Drug Delivery: Liposome Market—Competitor Market Shares 2009
CHAPTER FOUR: POLYMER DRUG DELIVERY
Table 4-1: Marketed Biodegradable Polymer Drugs, as of October 2010
Table 4-2: Marketed Nano- and Micro-particle Drugs, as of October 2010
Table 4-3: Marketed PEGylated Drugs, as of October 2010
Table 4-4: Marketed Hydrogel Polymer Drugs, as of October 2010
Table 4-5: Marketed Emulsions, as of October 2010
Table 4-6: New Developments in Polymers
Table 4-7: The Global Market for Polymers 2006-2014
Figure 4-1: The Global Market for Polymers 2006-2014
Table 4-8: Market for Polymers by Product Type 2006-2014
Figure 4-2: Market for Polymers by Product Type 2006-2014
Figure 4-3: Market for Polymers by Product Type 2010
Table 4-9: The Global Market for Polymers by Indication, 2006-2010
Figure 4-4: The Global Market for Polymers by Indication, 2006-2010
Figure 4-5: Market for Polymers by Indication 2006
Figure 4-6: Market for Polymers by Indication 2010
Table 4-10: Advanced Drug Delivery: Polymer Market—Competitors Revenues and Market Shares 2009
Figure 4-7: Advanced Drug Delivery: Polymer Market—Competitor Market Shares 2009
CHAPTER FIVE: MONOCLONAL ANTIBODY DRUG DELIVERY
Table 5-1: Key Marketed Monoclonal Antibodies, as of October 2010
Table 5-2: New Developments in Monoclonal Antibodies
Table 5-3: The Global Market for Monoclonal Antibodies 2006-2014
Figure 5-1: The Global Market for Monoclonal Antibodies 2006-2014
Table 5-4: The Global Market for Monoclonal Antibodies by Indication, 2006-2010
Figure 5-2: The Global Market for Monoclonal Antibodies by Indication, 2006-2010
Figure 5-3: Market for Monoclonal Antibodies by Indication 2006
Figure 5-4: Market for Monoclonal Antibodies by Indication 2010
Table 5-5: Advanced Drug Delivery: Monoclonal Antibody Market—Competitors Revenues and Market Shares 2009
Figure 5-5: 108 Advanced Drug Delivery: Monoclonal Antibody Market—Competitor Market Shares 2009
CHAPTER SIX: TRENDS AND TECHNOLOGY DEVELOPMENTS
Table 6-1: Nanotechnology Drug Delivery 2010, Companies and Technology
CHAPTER SEVEN: MARKET SIZE AND GROWTH
Table 7-1: The Worldwide Market for Advanced Drug Delivery Systems Revenues by Type 2006-2014
Figure 7-1: 1 The Worldwide Market for Advanced Drug Delivery Systems Revenues by Type 2006-2014
Table 7-2: The Worldwide Market for Advanced Drug Delivery Systems Market Share by Type 2006-2014
Figure 7-2: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2006
Figure 7-3: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2010
Figure 7-4: The Worldwide Market for Advanced Drug Delivery Systems Share by Type 2014
Table 7-3: Worldwide Advanced Drug Delivery by Geographical Region, 2006-2010
Figure 7-5: Worldwide Advanced Drug Delivery by Geographical Region, Sales by Region, 2006-2010
Figure 7-6: Worldwide Advanced Drug Delivery by Geographical Region, Percent Sales by Region 2006
Figure 7-7: Worldwide Advanced Drug Delivery by Geographical Region, Percent Sales by Region 2010
Table 7-4: Worldwide Market for Advanced Drug Delivery System Revenues and Market Share by Supplier 2009
Figure 7-8: Worldwide Market for Advanced Drug Delivery Systems Market Share by Leading Supplier 2009
